NVIDIA partners with Amgen to build generative AI models for drug discovery

US-based technology company NVIDIA has entered a collaboration with Amgen to build artificial intelligence (AI) models.  

Amgen will deploy the AI model-building platform, named Freyja, at the deCODE genetics headquarters in Reykjavik, Iceland. The system aims to analyse extensive human datasets for drug targets and biomarker discovery, facilitating diagnostics for disease progression and regression. 

The integration of NVIDIA’s DGX SuperPOD data platform with 31 DGX X100 nodes and 248 H100 Tensor Core GPUs will expedite the training of advanced AI models.  

NVIDIA also announced several other developments at the conference, including that its BioNeMo service generative AI platform is now in beta, featuring fresh foundational models and introducing a new hosted model by Recursion specifically designed for target and lead identification. 

In the announcement accompanying the collaboration, executive vice president and chief technology officer at Amgen David Reese said: “For more than a decade, Amgen has been preparing for this hinge moment we are seeing in the industry, powered by the union of technology and biotechnology.” 

In November 2023, Amgen teamed up with India-headquartered L&T Technology Services Limited (LTTS) to develop software to support and enhance medical imaging for endoscopies. As part of the agreement, NVIDIA will supply its Holoscan software and NVIDIA IGX Orin hardware, an AI technology used in the medical imaging sector. 

NVIDIA partnered with Flywheel, a US-based medical imaging AI platform alongside Microsoft in the same month.  

AI is a key theme at the 2024 J P Morgan healthcare conference, running from 8-10 January 2024 in San Francisco.  

Other developments announced at the conference include Mayo Clinic teaming up with AI startup Cerebras System to develop a foundation model, and Caris Life Sciences and ConcertAI signing a multi-year deal to offer up their databases to support AbbVie’s work to develop novel cancer drugs. 

According to a report on GlobalData’s Pharma Intelligence Center, the AI market was worth $81.3bn in 2022. By 2030, it is forecast to grow at a compound annual growth rate (CAGR) of 35.2% to $908.7bn. 

<!– –>

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: https://www.medicaldevice-network.com/news/nvidia-partners-with-amgen-to-build-generative-ai-models-for-drug-discovery/